Soligenix's COVID-19 Vaccine Candidate As Booster Neutralizes Delta, Omicron Variants

Soligenix Inc SNGX announced the results of a booster vaccination study using CiVax (heat-stable COVID-19 subunit vaccine program) in non-human primates (NHPs).
The data demonstrated rapid enhancement of neutralizing antibody responses to SARS-CoV-2, including against Delta and Omicron variants.
The NHPs had been double vaccinated with an adenovirus vaccine for COVID-19 seven months previously.
Before administering the booster vaccine, neutralizing antibody levels against the original and Delta strains were low but detectable and undetectable for the omicron strain.
Within one week of receiving the booster, neutralizing antibody levels increased 27-fold against the original and Delta strains. By three weeks, this increased up to 243-fold.
Protective neutralizing antibody levels were also rapidly raised against omicron by one-week post-vaccination.
Price Action: SNGX shares are up 0.99% at $0.69 during the market session on the last check Thursday.